Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T11:04:46.612Z Has data issue: false hasContentIssue false
  • English
  • Français

Placebo-controlled trial of moclobemide in social phobia

Published online by Cambridge University Press:  03 January 2018

Franklin R. Schneier ,
Deborah Goetz ,
Raphael Campeas ,
Randall Marshall ,
Brian Fallon  and
Michael R. Liebowitz
Franklin R. Schneier*
Affiliation:
Department of Therapeutics, New York State Psychiatric Institute; Department of Psychiatry, College of Physicians and Surgeons of Columbia University
Deborah Goetz
Affiliation:
Department of Therapeutics, New York State Psychiatric Institute; Department of Psychiatry, College of Physicians and Surgeons of Columbia University
Raphael Campeas
Affiliation:
Department of Therapeutics, New York State Psychiatric Institute; Department of Psychiatry, College of Physicians and Surgeons of Columbia University
Randall Marshall
Affiliation:
Department of Therapeutics, New York State Psychiatric Institute; Department of Psychiatry, College of Physicians and Surgeons of Columbia University
Brian Fallon
Affiliation:
Department of Therapeutics, New York State Psychiatric Institute; Department of Psychiatry, College of Physicians and Surgeons of Columbia University
Michael R. Liebowitz
Affiliation:
Department of Therapeutics, New York State Psychiatric Institute; Department of Psychiatry, College of Physicians and Surgeons of Columbia University
*
Franklin R. Schneier, Anxiety Disorders Clinic, New York State Psychiatric Institute, 722 West 168th Street. New York, NY 10032, USA. Fax: 212 923-2417; e-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Moclobemide, a reversible inhibitor of monoamine oxidase A, previously has been reported to have efficacy in the treatment of social phobia.

Method

Seventy-seven non-responders to one week of single-blind placebo were randomly assigned to moclobemide or placebo for eight weeks of double-blind treatment. Outcome was assessed by independent evaluator, treating psychiatrist and self-ratings. After eight weeks, patients who were at least minimally improved continued treatment for a further eight weeks.

Results

Intention-to-treat sample response rates at week 8 were 7/40 (17.5%) for the moclobemide group and 5/37 (13.5%) for placebo (NS). Moclobemide was significantly superior to placebo on 2 of 10 primary outcome measures. Moclobemide was well tolerated.

Conclusions

Moclobemide may have efficacy in the treatment of social phobia, but absence of significant differences on most primary outcome measures and small effect sizes for all outcome measures suggest that the magnitude of its clinical effect is small.

Type
Papers
Information
The British Journal of Psychiatry , Volume 172 , Issue 1 , January 1998 , pp. 70 - 77
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

∗

This paper was presented in part at the Annual Meeting of the American Psychiatric Association, New York, May 1996.

References

American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM – III – R). Washington, DC: APA.Google Scholar
Beck, A. T., Ward, C. H., Mendelsohn, M., et al (1961) An inventory for measuring depression. Archives of General Psychiatry, 31, 319–325.CrossRefGoogle Scholar
Bisserbe, J.-C., Lepine, J.-P. & the GRP Group (1994) Moclobemide in social phobia: a pilot open study. Clinical Neuropharmacology, 17 (suppl. 1), S88–S94.CrossRefGoogle ScholarPubMed
Davidson, J. R. T., Potts, N., Richichi, E., et al (1993) Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology, 13, 423–428.Google Scholar
Derogatis, L. R. (1983) SCL-90-R. Administration, Scoring, and Procedures Manual. Towson, MD: Clinical Psychometric Press.Google Scholar
Fahlen, T., Nilsson, H. L., Borg, K., et al (1995) Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatrica Scandinavica, 92, 351–358.CrossRefGoogle ScholarPubMed
Gelernter, C. S., Uhde, T. W., Cimbolic, P., et al (1991) Cognitive–behavioral and pharmacological treatments of social phobia: a controlled study. Archives of General Psychiatry, 48, 938–945.Google Scholar
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology, pp. 217–222. Washington, DC: Department of Health, Education and Welfare Publications (ADM) 76–338.Google Scholar
Hamilton, M. (1959) The assessment of anxiety states by rating. British Journal of Medical Psychology, 32, 50–55.Google Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology. Neurosurgery and Psychiatry, 23, 56–62.CrossRefGoogle ScholarPubMed
Heimberg, R. G., Dodge, C. S., Hope, D. A., et al (1990) Cognitive behavioral treatment of social phobia: comparison to a credible placebo control. Cognitive Therapy and Research, 14, 1–23.CrossRefGoogle Scholar
International Multicenter Clinical Trial Group on Moclobemide in Social Phobia (1997) Moclobemide in social phobia. A double-blind, placebo controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience, 24, 71–80.Google Scholar
Johnson, P. O. & Neyman, J. (1926) Tests of certain linear hypotheses and their application to some educational problems. Stat Res Memoirs, 1, 57–93.Google Scholar
Kessler, R. C., McGonagle, K. A., Zhao, A., et al (1994) Lifetime and 12-month prevalence of DSM–III–R psychiatric disorders in the United States. Archives of General Psychiatry, 51, 8–19.CrossRefGoogle ScholarPubMed
Korn, A., Da Prada, M., Raffesberg, W., et al (1988) Tyramine pressor effect in man: studies with moclobemide, a novel reversible monoamine oxidase inhibitor. Journal of Neural Transmission, suppl. 26, 57–71.Google Scholar
Liebowitz, M. R. (1987) Social phobia. Modern Problems in Pharmacopsychiatry, 22, 141–173.Google Scholar
Liebowitz, M. R., Gorman, J. M., Fyer, A. J., et al (1988) Pharmacotherapy of social phobia: an interim report of a placebo controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry, 49, 252–257.Google ScholarPubMed
Liebowitz, M. R., Schneier, F., Campeas, R., et al (1992) Phenelzine vs. atenolol in social phobia: A placebo-controlled comparison. Archives of General Psychiatry, 49, 290–300.Google Scholar
Lonnqvist, J., Sihvo, S., Syvalahti, E., et al (1993) Moclobemide and fluoxetine in atypical depression: A double-blind study. Journal of Affective Disorders, 32, 169–177.CrossRefGoogle Scholar
Lott, M., Greist, J. H., Jefferson, J. W., et al (1997) Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study. Journal of Clinical Psychopharmacology, 17, 255–260.Google Scholar
Marks, I. M. & Matthews, A. M. (1982) Brief standard self-rating for phobic patients. Behaviour Research and Therapy, 17, 263–267.CrossRefGoogle Scholar
Noyes, R., Morox, G., Davidson, J. R. T., et al (1997) Moclobemide in social phobia: A controlled dose-response trial. Journal of Clinical Psychopharmacology, 17, 247–254.Google Scholar
Schneier, F. R., Heckelman, L. R., Garfinkel, R., et al (1994) Functional impairment in social phobia. Journal of Clinical Psychiatry, 55, 322–331.Google Scholar
Sheehan, D. (1983) The Anxiety Disease, pp. 148–149. New York: Scribner.Google Scholar
Spitzer, R., Williams, J. B. & Gibbon, M. (1987) Structured Clinical Interview of DSM–III–R (SCID–I). New York: Biometrics Research Department, New York Psychiatric Institute.Google Scholar
Spitzer, R., Williams, J. B. & Gibbon, M., et al (1990) Structural Clinical Interview of DSM–III–R Axis II Disorders (SCID–II). Washington, DC: American Psychiatric Press.Google Scholar
Turner, S. M., Beidel, D. C. & Jacob, R. G. (1994) Social phobia: a comparison of behavior therapy and atenolol. Journal of Consulting and Clinical Psychology, 62, 350–358.Google Scholar
Van Vliet, I. M., den Boer, J. A. & Westenberg, H. G. M. (1992) Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. European Neuropsychopharmacology, 2, 21–29.CrossRefGoogle ScholarPubMed
Van Vliet, I. M., den Boer, J. A. & Westenberg, H. G. M. (1994) Psychopharmacological treatment of social phobia: a double-blind, placebo-controlled study with fluvoxamine. Psychopharmocology, 115, 128–134.Google Scholar
Versiani, M., Nardi, A. E., Mundim, F. D., et al (1992) Pharmacotherapy of social phobia: A controlled study with moclobemide and phenelzine. British Journal of Psychiatry, 161, 353–360.CrossRefGoogle ScholarPubMed
Versiani, M., Nardi, A. E., Mundim, F. D., et al (1996) The long-term treatment of social phobia with moclobemide. International Clinical Psychopharmocology, 11 (suppl. 3), 83–88.Google Scholar
Waldmeier, P. C. (1967) Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). Journal of Neural Transmission, suppl. 23, 55–72.Google Scholar
Waldmeier, P. C., Glatt, A., Jaekel, J., et al (1993) Brofaromine: A monoamine oxidase-A and serotonin uptake inhibitor. Clinical Neuropharmacology, 16 (suppl. 2), S19–S24.Google ScholarPubMed
Watson, P. & Friend, R. (1969) Measurement of social-evaluative anxiety. Journal of Consulting and Clinical Psychology, 33, 448–457.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.